PharmaEssentia’s Besremi receives FDA approval for ET
RegulatoryapprovedBesremiPositive
AI Analysis
Summary
The FDA approved PharmaEssentia's Besremi (ropeginterferon alfa-2b-njft) for the treatment of adults with essential thrombocythaemia, marking a regulatory milestone for the company.
Outcome Details
FDA approval for treatment of adults with essential thrombocythaemia
Importance:8/10
Sentiment:
0.90
FDA approvalessential thrombocythaemiaropeginterferon alfa-2b-njft
Read the original article
Published by Pharmaceutical Technology on September 1, 2026 9:05 AM